MENGENAI EPISOD INI
Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.
Bahasa Inggeris
Amerika Syarikat
TRANSKRIP 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CARI EPISOD LEPAS
Cari episod lepas bagi Pharmaceutical Executive.
EPISOD LAIN DALAM PODCAST INI
Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.
Bausch + Lomb names Thomas Appio interim CEO as Brent Saunders departs, a Pharm Exec interview explores how AI is reshaping entry-level apprenticeship in professional services, and a LogiPharma 2026 conversation makes the case against waiting for perfect data to deploy AI in pharma supply chains.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Penafian: Podcast dan karya seni yang dibenamkan pada halaman ini adalah daripada Pharmaceutical Executive Podcast, yang merupakan hak milik pemiliknya dan tidak bergabung dengan atau disokong oleh Listen Notes, Inc.
SUNTING
Terima kasih kerana membantu memastikan pangkalan data podcast dalam keadaan terkini.
